請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43622完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 于明暉 | |
| dc.contributor.author | Chia-Chi Liu | en |
| dc.contributor.author | 劉家綺 | zh_TW |
| dc.date.accessioned | 2021-06-15T02:24:34Z | - |
| dc.date.available | 2019-08-17 | |
| dc.date.copyright | 2009-09-16 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-08-18 | |
| dc.identifier.citation | 1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38.
2. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-4. 3. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15 Suppl:E3-6. 4. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993;262:369-70. 5. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ. Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008;28:175-88. 6. Lee HC, Suh DJ. Lamivudine therapy for decompensated liver cirrhosis related to hepatitis B virus infection. Intervirology 2003;46:388-93. 7. Yu M-W, Hsu F-C, Sheen IS, Chu C-M, Lin D-Y, Chen C-J, et al. Prospective Study of Hepatocellular Carcinoma and Liver Cirrhosis in Asymptomatic Chronic Hepatitis B Virus Carriers. Am. J. Epidemiol. 1997;145:1039-1047. 8. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-801. 9. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-9. 10. Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 1978;74:103-6. 11. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8. 12. Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008;5:95-106. 13. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92. 14. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003;163:218-24. 15. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-75. 16. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99:1160-74. 17. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci U S A 1985;82:8681-5. 18. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18. 19. Vinas O, Bataller R, Sancho-Bru P, Gines P, Berenguer C, Enrich C, et al. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 2003;38:919-29. 20. Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, Zhang CL, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998;153:1895-902. 21. Shiraishi T, Morimoto S, Koh E, Fukuo K, Ogihara T. Increased release of platelet-derived growth factor from platelets in chronic liver disease. Eur J Clin Chem Clin Biochem 1994;32:5-9. 22. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349-51. 23. Cara LM. Serum cytokines as biomarkers of disease and clues to pathogenesis. Hepatology 2007;46:6-8. 24. Iacobellis A, Mangia A, Leandro G, Clemente R, Festa V, Attino V, et al. External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis. Am J Gastroenterol 2005;100:868-73. 25. Tarik A, Ivan B, Ingrid L, Valerie P, Dominique V, Claude D, et al. Liver Gene Expression Signature of Mild Fibrosis in Patients With Chronic Hepatitis C. Gastroenterology 2005;129:2064-2075. 26. Julie P, Indra Neil G, Paul R, William R. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. Journal of Hepatology 2006;44:462-474. 27. Wu C-F, Yu M-W, Lin C-L, Liu C-J, Shih W-L, Tsai K-S, et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29:106-112. 28. Poynard T, Ratziu V, Benhamou Y, Opolon P, Cacoub P, Bedossa P. Natural history of HCV infection. Baillieres Best Pract Res Clin Gastroenterol 2000;14:211-28. 29. Tarik A, Ivan B, Valerie P, Pierre B, Michel V, Patrick M. Genetics, Genomics, and Proteomics: Implications for the Diagnosis and the Treatment of Chronic Hepatitis C. Semin Liver Dis 2007:013-027. 30. Davenport M, Gonde C, Narayanaswamy B, Mieli-Vergani G, Tredger JM. Soluble adhesion molecule profiling in preoperative infants with biliary atresia. J Pediatr Surg 2005;40:1464-9. 31. Casasnovas JM, Springer TA, Liu JH, Harrison SC, Wang JH. Crystal structure of ICAM-2 reveals a distinctive integrin recognition surface. Nature 1997;387:312-5. 32. Mas VR, Maluf DG, Archer KJ, Yanek KC, Fisher RA. Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. Transplantation 2007;84:1262-71. 33. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001;21:373-84. 34. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;277:11069-76. 35. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret M-N, et al. Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid. The American Journal of Gastroenterology 2004;99:271-279. 36. Shigeki Kuriyama FY, Hideyuki Inoue, Jitsuko Takano, Mutsumi Ogawa, Yuko Kita, Hitoshi Yoshiji, Akihiro Deguchi, Yasuhiko Kimura, Takashi Himoto, Hirohito Yoneyama, Kazutaka Kurokohchi, Tsutomu Masaki, Naohito Uchida, Seishiro Watanabe. Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-β1 in hepatofibrogenesis of a rat cirrhosis model. International Journal of Molecular Medicine 2007;19:317-24. 37. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, et al. Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. JAMA 2008;299:53-60. 38. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998;152:423-30. 39. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003;125:1085-93. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43622 | - |
| dc.description.abstract | Background Early identification of high risk population for liver cirrhosis may be beneficial to hepatitis B virus (HBV) carriers and their prognosis on hepatocellular carcinoma (HCC). We aimed to identify differently expressed cytokines in plasma between clinical liver cirrhosis patients and asymptomatic HBV carriers as biomarkers for HCC prediction. Methods A total of 174 cytokines were assessed in plasma from 16 HBsAg carriers at different stages of liver cirrhosis using cytokine antibody microarrays. Ten promising cytokines were later evaluated in a case-control study including 49 HCC cases and 50 matched controls nested within a longitudinal cohort study of HBsAg carriers by using quantitative antibody arrays. Blood samples from each study subject were collected up to 16 years before diagnosis of HCC. Results Forty-five cytokines were differentially expressed among asymptomatic carriers, Child-Pugh stage A patients and Child-Pugh stage B/C patients (parametric P-value range: 0.0006-0.0487, empirical P-value range: 0.0003-0.0556, false-discovery rate q-value range=0.0713-0.1244). Evaluation of a subset of 10 cytokines, including ICAM-2, MCP-1, EGF, CXCL-16, IGFBP-2, sTNFRII, TIMP4, Fas, RANTES, and TIMP-1, by a nested case-control study showed that only plasma ICAM-2 levels were significantly different between HCC cases and controls at baseline (P-value for Wilcoxon sum rank test = 0.0413). Plasma ICAM-2 levels exhibited an accuracy (AUC=0.6208) comparable to HBV viral load (AUC=0.6022) and superior to serum ALT (AUC=0.5965) for prediction of HCC. Conclusion Results of this study suggested that ICAM-2 may serve as a promising noninvasive biomarker for prediction of HCC development. Key Words Cytokines, Hepatitis B, liver cirrhosis, hepatocellular carcinoma, microarrays | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T02:24:34Z (GMT). No. of bitstreams: 1 ntu-98-R95842005-1.pdf: 779621 bytes, checksum: eaa99b9c5a487078ea4f5469fa0c080c (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 目錄
誌謝……………………………………………………………………. i 中文摘要………………………………………………………………. ii 英文摘要………………………………………………………………. iii 背景介紹…………………………………………….………………… 1 材料與方法……………………………………………………………. 4 結果……………………………………………………………………. 8 討論……………………………………………………………………. 11 參考文獻………………………………………………………………. 15 圖表目錄 表一、Significant Cytokines......................................................................19 表二、Class Prediction by Different Cytokine Sets...................................20 表三、Median Levels of Cytokines in Cases and Controls........................21 表四、Cytokine Levels and HCC Related Risk Factors............................22 表五、Comparison of AUC........................................................................23 表六、Discriminant Performance of ICAM-2............................................24 圖一、Flow Chart and Study Design.........................................................25 圖二、Selection of Cytokines.....................................................................26 圖三、Canonical Pathway Analysis of IPA................................................27 圖四、Cytokines involved in the pathway of hepatic stellate cells activation .........................................................................................................28 圖五、Role of ICAM-2 in the Network.....................................................29 附錄一、Inclusion Criteria of the First Stage............................................30 附錄二、Inclusion Criteria of the Second Stage........................................31 附錄三、List of 174 Cytokines..................................................................32 附錄四、R Square of Quantitative Microarrays.........................................35 | |
| dc.language.iso | en | |
| dc.subject | B型肝炎 | zh_TW |
| dc.subject | 肝硬化 | zh_TW |
| dc.subject | 肝癌 | zh_TW |
| dc.subject | 微陣列晶片 | zh_TW |
| dc.subject | 細胞激素 | zh_TW |
| dc.subject | microarrays | en |
| dc.subject | Cytokines | en |
| dc.subject | liver cirrhosis | en |
| dc.subject | hepatocellular carcinoma | en |
| dc.subject | Hepatitis B | en |
| dc.title | 肝硬化相關細胞激素對B型肝炎誘導肝細胞癌之預測：蛋白質微陣列分析 | zh_TW |
| dc.title | Identification of Cytokines Involved in HBV-Related Cirrhosis for Hepatocellular Carcinoma Prediction: A Protein Microarray Analysis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 莊曜宇 | |
| dc.contributor.oralexamcommittee | 蔡孟勳,劉力瑜,林志陵 | |
| dc.subject.keyword | 細胞激素,B型肝炎,肝硬化,肝癌,微陣列晶片, | zh_TW |
| dc.subject.keyword | Cytokines,Hepatitis B,liver cirrhosis,hepatocellular carcinoma,microarrays, | en |
| dc.relation.page | 35 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-08-18 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學研究所 | zh_TW |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 761.35 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。